Fortress Biotech (FBIO) Liabilities from Discontinued Operations (2017)
Fortress Biotech (FBIO) posted quarterly Liabilities from Discontinued Operations of 29283000.0 for Q4 2017.
Powered by 
Analysis
Fortress Biotech (FBIO) Liabilities from Discontinued Operations (2017) Analysis & Trends
Fortress Biotech's Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 29283000.0 for Q4 2017.
- In Q4 2017, Liabilities from Discontinued Operations changed N/A year-over-year to 29283000.0; the TTM figure through Dec 2017 stood at 29283000.0 (changed N/A YoY), while the FY2017 annual figure was 29283000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q4 2017 stood at 29283000.0.
- The five-year high for Liabilities from Discontinued Operations was 29283000.0 in Q4 2017, with the low at 29283000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn |